Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Pestrin

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Breast Cancer Research and Treatment|April 6, 2012
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept studyMarta Pestrin, Silvia Bessi, Fabio Puglisi, et al.
Plos One|January 26, 2011
HER2-positive circulating tumor cells in breast cancerMichail Ignatiadis, Françoise Rothé, Carole Chaboteaux, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2019
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)Amelia McCartney, Chiara Biagioni, Gaia Schiavon, et al.
Breast Cancer Research : BCR|May 31, 2019
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trialLorenzo Rossi, Chiara Biagioni, Amelia McCartney, et al.
Breast Cancer Research : BCR|April 25, 2014
International study on inter-reader variability for circulating tumor cells in breast cancerMichail Ignatiadis, Sabine Riethdorf, François-Clement Bidard, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Breast Cancer Research and Treatment|April 6, 2012
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept studyMarta Pestrin, Silvia Bessi, Fabio Puglisi, et al.
Plos One|January 26, 2011
HER2-positive circulating tumor cells in breast cancerMichail Ignatiadis, Françoise Rothé, Carole Chaboteaux, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2019
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)Amelia McCartney, Chiara Biagioni, Gaia Schiavon, et al.
Breast Cancer Research : BCR|May 31, 2019
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trialLorenzo Rossi, Chiara Biagioni, Amelia McCartney, et al.
Breast Cancer Research : BCR|April 25, 2014
International study on inter-reader variability for circulating tumor cells in breast cancerMichail Ignatiadis, Sabine Riethdorf, François-Clement Bidard, et al.
Pageof 4